Expanding Clinical Network Sarah Cannon Research Institute collaborates with numerous community-based healthcare providers and has a broad clinical trial network across over 200 locations in more than 20 states, presenting significant partnership opportunities for organizations seeking to expand trial access and operational reach.

Strategic Industry Partnerships Recent collaborations with major pharmaceutical companies like Bristol-Myers Squibb and various regional cancer centers highlight SCRI's strong industry relationships, making them an ideal partner for organizations aiming to enhance research credibility and market access in oncology.

Innovative Research Leadership With over 850 first-in-human clinical trials conducted and a focus on novel cancer therapies, SCRI offers potential for collaboration with biotech firms and startups interested in pioneering oncology research and gaining early access to clinical development events.

Robust Market Presence Operating in a competitive sector with revenue between 250 million to 500 million and a substantial employee base, SCRI’s established reputation in oncology research makes it a valuable partner for organizations looking to expand their influence in cancer treatment research.

Technological Infrastructure Utilizing a diverse tech stack including Veeva Systems, NoSQL, and PostgreSQL, SCRI demonstrates a commitment to advanced data management and analytics, which presents opportunities for technology vendors and data service providers to supply innovative solutions tailored to clinical trial needs.